EMERGENCY MEETING NOTICE

MARCH 22, 2020
9:00 a.m.

LOCATION:

This meeting is being convened telephonically, consistent with the March 13, 2020 guidance of Ohio Attorney General Dave Yost.

Join by phone:
Dial In Information: (614) 721-2972
Conference ID: 77348039

PURPOSE:

The State of Ohio Board of Pharmacy has received reports of a significant increase in the prescribing of chloroquine or hydroxychloroquine as a result of the COVID-19 outbreak.

To address this increased demand, the Board is holding an emergency meeting to review proposed language and pursue an emergency filing of rule 4729-5-30.2 of the Ohio Administrative Code.

The Board’s consideration of this rule and request for an emergency order from Governor DeWine will ensure that these drugs are not being stockpiled and continue to be dispensed appropriately to patients who rely on these medications, as they are used to treat conditions such as: malaria, rheumatoid arthritis, and lupus.

In addition to the emergency rule provisions in section 119.03 of the Revised Code, section 4729.26 of the Revised Code provides the Board with broad rule making authority to implement the provisions of its chapter governing the practice of pharmacy and the distribution of dangerous drugs (i.e. prescription drugs):

4729.26 Administrative rules.

The state board of pharmacy may adopt rules in accordance with Chapter 119. of the Revised Code, not inconsistent with the law, as may be necessary to carry out the purposes of and to enforce the provisions of this chapter. The rules shall be published and made available by the board to each pharmacist licensed under this chapter.
4729-5-30.02 - Prescription requirements for chloroquine or hydroxychloroquine (DRAFT)

(A) Unless otherwise approved by the Board’s executive director, no prescription for chloroquine or hydroxychloroquine may be dispensed by a pharmacist or sold at retail by a licensed terminal distributor of dangerous drugs for a COVID-19 diagnosis unless all the following apply:

1) The prescription bears a written diagnosis code from the prescriber;
2) The diagnosis has been confirmed by a positive test result, which is documented on the prescription;
3) The prescription is limited to no more than a fourteen-day supply, and
4) No refills may be permitted unless a new prescription is furnished.

B) Prescriptions for either presumptive positive patients or prophylactic use of chloroquine or hydroxychloroquine related to COVID-19 is strictly prohibited unless otherwise approved by the Board’s Executive Director in consultation with the Board President, at which time a resolution shall issue.